Opinion

Video

Overview of Abiraterone and the Differences Between Formulations

Author(s):

Gautam Jayram, MD,Christopher Pieczonka, MD

This discussion provides an overview of abiraterone and the key differences between micronized and non-micronized formulations, including considerations for choosing between the two formulations.

  • Please provide a brief overview of abiraterone and the key differences between micronized and non-micronized formulations.
  • How do you approach deciding between the 2 formulations (micronized vs non-micronized)?

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Medcast series
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
Related Content
Agreement reached for public reimbursement of Pluvicto in Canada
December 17th 2024

Agreement reached for public reimbursement of Pluvicto in Canada

Hannah Clarke
Pluvicto was approved by Health Canada in August 2022.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Adding CAN-2409 to radiation improves DFS in localized prostate cancer
December 13th 2024

Adding CAN-2409 to radiation improves DFS in localized prostate cancer

Hannah Clarke
“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
FDA grants clearance to NanoKnife System for prostate tissue ablation
December 9th 2024

FDA grants clearance to NanoKnife System for prostate tissue ablation

Hannah Clarke
The clearance is supported by data from the PRESERVE trial, which evaluated the safety and effectiveness of the NanoKnife System in patients with intermediate-risk prostate cancer.
FDA fast tracks PT217 for neuroendocrine prostate cancer
December 5th 2024

FDA fast tracks PT217 for neuroendocrine prostate cancer

Hannah Clarke
PT217 is currently under investigation in the phase 1/2 SKYBRIDGE trial in patients with neuroendocrine cancers.
© 2024 MJH Life Sciences

All rights reserved.